Loading organizations...
§ Private Profile · Marlborough, MA, USA
Medical device company develops and manufactures minimally invasive medical devices, focusing on cardiology.
Marlborough, Massachusetts-based Boston Scientific Cardiology develops and manufactures minimally invasive medical devices, specializing in steerable catheters and advanced treatments for cardiovascular, respiratory, and gastrointestinal conditions. The publicly traded corporation operates at a massive global scale, generating $8.4 billion in annual revenue and employing approximately 27,000 people as of 2016. The enterprise supplies its specialized surgical equipment directly to hospitals, healthcare providers, and physicians performing complex, less invasive procedures. Initially capitalized with $300,000 from its creators and $500,000 in bank loans, the firm later raised over $400 million during its 1992 initial public offering and commercialized the foundational catheter technology invented by Itzak Bentov. Originally established in Watertown, the medical device manufacturer grew early revenues from $2 million in its first year to $16 million by 1983. Boston Scientific was founded in 1979 by John Abele and Peter Nicholas.
Boston Scientific Cardiology has raised $6.0M across 2 funding rounds.
Key people at Boston Scientific Cardiology.
Boston Scientific Cardiology was founded in 1979 by John Abele (Founder).
Boston Scientific Cardiology has raised $6.0M in total across 2 funding rounds.
Key people at Boston Scientific Cardiology.
Boston Scientific Cardiology has raised $6.0M across 2 funding rounds. Most recently, it raised $4.0M BSX - Seed in August 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2024 | $4M Seed | — | CMCC Global, CoinFund, Electric Capital, Polychain Capital, Seed Club Ventures, Ryan Zurrer, Nicolas Pinto, Zach Segal | Announced |
| Dec 1, 2022 | $2M Seed | — | CMCC Global, CoinFund, Electric Capital, Polychain Capital, Seed Club Ventures, Ryan Zurrer, Nicolas Pinto, Zach Segal | Announced |
Boston Scientific's Interventional Cardiology division develops and provides minimally invasive technologies for diagnosing and treating heart and vascular conditions, including coronary artery disease, acute myocardial infarction, and in-stent restenosis.[1][2] It serves healthcare professionals and patients worldwide, solving critical problems in cardiovascular care by improving clinical outcomes, expanding access to treatments, reducing healthcare costs, and enabling healthier lives for millions.[1][2][3] As part of Boston Scientific's core businesses—which also include Cardiac Rhythm Management, Electrophysiology, and Peripheral Interventions—this division contributes to the company's $16.7B in 2024 net sales, supported by $1.6B in R&D investment and ~100 new product launches that year.[3][4] With 53K employees across 127 countries treating over 44M patients annually, the division drives growth through a broad portfolio of percutaneous coronary intervention (PCI) devices, training, and clinical solutions.[4][5]
Boston Scientific, founded in 1979, evolved into a global medtech leader through relentless innovation in minimally invasive therapies, with Interventional Cardiology emerging as a core business focused on heart and vascular advancements.[3][4] The company's backstory traces to pioneers like John Abele and Herman "Dutch" Kuizen, who emphasized less invasive solutions to transform patient care—principles that now define the cardiology portfolio's commitment to tools reducing procedural risks and costs.[1][4] Pivotal moments include expanding from early balloon angioplasty technologies to today's comprehensive PCI suite, amid growing demands for efficient cath lab interventions, backed by ongoing R&D that launched numerous products in 2024.[4][5]
Boston Scientific's Interventional Cardiology rides the wave of advancing minimally invasive cardiovascular tech, amid rising global cardiovascular disease prevalence and demands for cost-effective, high-efficiency procedures.[1][2] Timing aligns with aging populations and post-pandemic shifts toward outpatient cath lab innovations, where market forces like value-based care favor their outcome-improving, cost-reducing solutions.[1][3] The division influences the ecosystem by collaborating with professionals worldwide, setting standards in PCI via data-driven tools, and contributing to Boston Scientific's reach in 127 countries—accelerating adoption of life-extending therapies.[3][4][5]
Boston Scientific's Interventional Cardiology is poised for sustained growth through R&D-fueled product expansions and global scaling, targeting complex cases with next-gen PCI innovations.[4][5] Trends like AI-enhanced imaging, personalized therapies, and expanded access in emerging markets will shape its trajectory, potentially boosting its role in treating escalating cardiovascular burdens.[1][2] As medtech evolves toward precision and efficiency, this division will amplify Boston Scientific's mission—advancing science for life with tools that deliver more time and quality for patients.[3][4]
Boston Scientific Cardiology was founded in 1979 by John Abele (Founder).
Boston Scientific Cardiology has raised $6.0M in total across 2 funding rounds.
Boston Scientific Cardiology's investors include CMCC Global, CoinFund, Electric Capital, Polychain Capital, Seed Club Ventures, Ryan Zurrer, Nicolas Pinto, Zach Segal.